Global Gabapentin Market Projected to Expand at 8.2% CAGR by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Gabapentin Market Size Likely To Evolve From 2025 Through 2034?

The gabapentin market size has shown robust expansion in recent years. It is anticipated to increase from $2.78 billion in 2024 to $3.01 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.5%. This historical growth can be linked to the rising prevalence of epilepsy, an uptick in the incidence of neuropathic pain, heightened awareness of neurological disorders, an expanding geriatric population, and the increased adoption of generic anticonvulsants.

The gabapentin market is poised for significant expansion in the coming years, with projections indicating a rise to $4.12 billion by 2029, at a compound annual growth rate (CAGR) of 8.2%. This anticipated growth throughout the forecast period stems from factors like the increasing need for chronic pain management, a growing number of approvals for gabapentin formulations, improved access to healthcare in developing areas, a heightened focus on personalized medicine, and the escalating burden of neurological disorders. Prominent trends for the forecast period include innovations in drug delivery systems, the incorporation of gabapentin into combination therapies, technology-driven research and development specifically for neuropathic pain, progress in extended-release formulations, and advancements in pharmacogenomics applications.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24544&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Gabapentin Industry?

The rising occurrence of epilepsy is projected to fuel the expansion of the gabapentin market in the future. This neurological condition, epilepsy, is characterized by recurrent seizures stemming from abnormal electrical signals within the brain. The increase in epilepsy incidents is largely attributable to the expanding older demographic, given that advancing age heightens the susceptibility to neurological ailments leading to seizures. Gabapentin manages epilepsy by moderating atypical neural activity in the brain and reducing signals that provoke seizures, working through targeting calcium channels to help avert the onset of seizures. As an illustration, in May 2024, data from the Centers for Disease Control and Prevention, a US-based government agency, indicated that approximately 2.9 million U.S. adults aged 18 and older reported having active epilepsy in 2022, marking an increase of 1.08% from 2021. Consequently, the growing prevalence of epilepsy is propelling the expansion of the gabapentin market.

What Are The Leading Segments Analyzed In The Gabapentin Market?

The gabapentin market covered in this report is segmented –

1) By Type: Generic, Branded

2) By Dosage Form: Tablet, Capsule, Oral Solution

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By Application: Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Other Applications

Subsegments:

1) By Generic: Gabapentin Immediate Release (IR), Gabapentin Extended Release (ER), Gabapentin Capsules, Gabapentin Tablets, Gabapentin Oral Solution

2) By Branded: Neurontin, Gralise, Horizant, Other Branded Formulations

What Are The Latest Industry Trends Transforming The Gabapentin Market?

Leading companies in the gabapentin market are increasingly concentrating on developing advanced formulations, such as bioequivalent tablets, to enhance therapeutic efficacy and broaden treatment options for various neurological conditions. These bioequivalent tablets are generic medications designed to deliver an identical dose of the active ingredient into the bloodstream with the same speed and efficiency as the branded version, thus assuring similar safety and therapeutic effects. For instance, in March 2024, Strides Pharma Science Limited, an India-based pharmaceutical company, launched Gabapentin Tablets USP in 600 mg and 800 mg strengths, after receiving approval from the United States Food & Drug Administration (USFDA) to expand its neurology portfolio in the US market. This innovative gabapentin offers enhanced bioavailability, precise dosing, and patient-friendly administration, which contributes to more consistent therapeutic outcomes, improved symptom control, and greater convenience for long-term therapy. Furthermore, Gabapentin tablets USP, 600 mg, provide versatile therapeutic potential, offering effective management for a range of neurological conditions, including neuropathic pain and partial seizures, through reliable dosing and proven clinical efficacy.

Who Are The Key Multinational Companies Dominating The Gabapentin Market?

Major companies operating in the gabapentin market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan Inc., Apotex Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Ipca Laboratories Private Limited, Granules India Limited, Medley Pharmaceuticals Limited, Wockhardt Limited, Epic Pharma LLC, Healing Pharma India Pvt. Ltd., Rochem International Inc., Accord Healthcare Limited, Strides Pharma Science Limited, Ascend Laboratories LLC

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/gabapentin-global-market-report

Which Region Currently Holds The Largest Share Of The Gabapentin Market?

North America was the largest region in the gabapentin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gabapentin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Gabapentin Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24544&type=smp

Browse Through More Reports Similar to the Global Gabapentin Market 2025, By The Business Research Company

Glycomic Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

Glycopeptide Antibiotics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report

Antiglaucoma Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795